Welcome to our dedicated page for Acrivon Therapeutics SEC filings (Ticker: ACRV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings can read like a graduate textbook—especially when Acrivon Therapeutics packs its 10-K with proteomics jargon, trial protocols, and liquidity tables. If you’re searching “Acrivon Therapeutics SEC filings explained simply� or wondering how platinum-resistant ovarian cancer data affects the balance sheet, you’re in the right place. Stock Titan’s AI dissects every page the moment it hits EDGAR, so you spend minutes—not hours—finding what matters.
Need to track “Acrivon Therapeutics insider trading Form 4 transactions� before the next readout? Our dashboard streams Form 4 insider transactions in real time, flags option exercises, and links them to upcoming milestones disclosed in 8-Ks. Curious about cash runway? The quarterly earnings report 10-Q filing is paired with plain-English summaries that spotlight R&D spend, burn rate, and AP3 platform progress. We also map risk-factor changes between annual report 10-K filings, highlight any shelf-registration clues in S-3s, and surface board votes from the latest proxy statement on executive compensation.
Whether you’re parsing an “Acrivon Therapeutics earnings report filing analysis,� monitoring “Acrivon Therapeutics executive stock transactions Form 4,� or decoding an “Acrivon Therapeutics 8-K material events explained,� Stock Titan delivers comprehensive coverage. Our AI-powered summaries translate dense pathway diagrams into actionable insights, while expert commentary points out dilution risk and regulatory catalysts. Set custom alerts to know the second a new study start appears, compare segment performance across periods, and keep a pulse on WEE1/PKMYT1 clinical updates. All ACRV filings, all in one place, always up to date.
Acrivon Therapeutics (ACRV) presented interim financials and clinical progress through June 30, 2025. The company recorded a six-month net loss of $40.7 million, bringing an accumulated deficit to $237.7 million, and reported cash, cash equivalents and investments of $147.6 million, which management says funds operations into the second quarter of 2027. Acrivon remains pre-revenue and continues to invest heavily in R&D.
Clinically, ACR-368 is in a registrational-intent Phase 2 program for endometrial cancer using the proprietary OncoSignature biomarker; an interim cohort of OncoSignature-positive patients showed a 35% confirmed overall response rate and tumor shrinkage in 80% of patients. ACR-2316 is in Phase 1 with early target engagement and a confirmed partial response observed at Dose Level 3. The company retains licensed rights to prexasertib under a Lilly agreement with up to $168 million in milestone payments and tiered royalties up to 10%.
This Schedule 13G/A reports that Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC and Frank M. Sands jointly beneficially own 2,122,605 shares of Acrivon Therapeutics common stock, representing 6.8% of the outstanding shares based on 31,355,361 shares reported by the issuer. The filing shows no sole voting or dispositive power and indicates shared voting and dispositive power over the reported shares, consistent with a passive investor position.
The filing names the reporting entities, identifies their places of organization (Cayman Islands, Delaware and United States), provides the issuer's principal office address, and includes a certification that the securities were not acquired to change or influence control of the issuer.
FAQ
What is the current stock price of Acrivon Therapeutics (ACRV)?
What is the market cap of Acrivon Therapeutics (ACRV)?
